Meet some of the executives behind some of San Diego's thriving technology and biotech companies, along with news about IP issues, the latest products and innovations.
Clinical trials are the lifeblood of biotech. Finding the right service providers (CROs, safety, IVRS, consultants, contract manufacturers and many others), as well as the right clinical investigators and sites, results in a complex web of legal obligations and potential liabilities. Limitation of liability clauses can reduce a party's exposure if a contractual obligation is breached. More often, limitations of liability provisions are used to shift risk to the sponsor of the clinical trial. But, if your contracts are well negotiated and drafted, the risks can be carefully and fairly allocated between the parties in a balanced and reasonable manner. Because of the complexity of the legal relationships and liabilities found in clinical trials, this article is limited to a brief description of limitation of liability clauses, and their general strengths and weaknesses.
When people think of art, they think of the Louvre. When people think of nature-inspired designs and solutions, they think of San Diego.
Amid economic gloom, there are bright spots for San Diego life sciences innovators. Industry fundamentals remain favorable, technological advances continue to be made and $10 billion in funding from the National Institutes of Health was approved in the economic stimulus package signed by President Barack Obama. For the ag-biotech and clean energy cluster growing here, federally guaranteed loans may help underwrite construction of projects with new technologies in renewable energy at a time when debt markets are closed.
The collapse of traditional financing markets has biotech executives in San Diego and the world over exploring alliances and creative collaborations as an alternative strategy to advance their products, or to simply keep the company alive until investor confidence in biotech returns.
With 13.8 million square feet of inventory, San Diego County ranks as the third largest biotech hub in the United States behind Boston/Cambridge and the San Francisco Bay Area. This number will continue to grow due to the county's exceptional roster of educational and research institutions and recognition as a desirable place to live and work.
Veralliance Properties is currently undertaking one of its largest and most ambitious building transformations in San Diego at its 465,000-square-foot Campus Pointe project located in the University Towne Center (UTC) area. The transformation has attracted biopharmaceutical corporation Eli Lilly and Co. (NYSE: LLY) to the site.
Heart disease and stroke continue to be the nation's No. 1 and 3 killers, and 142 million American adults -- 66 percent of Americans -- are overweight. Physical inactivity is a major risk factor for heart disease, and is a comparable risk to other modifiable risk factors such as high blood cholesterol, high blood pressure and smoking. About 70 percent of the American population engages in no regular leisure-time physical activity, which is defined as light-moderate activity for more than 30 minutes, five times a week, or vigorous activity (like brisk walking) for more than 20 minutes, three times a week.
A comprehensive patent strategy requires managing all aspects of a patent portfolio, from correctly identifying inventors and their assignment obligations to tracking priority of claimed subject matter. Overlooking these issues can have detrimental effects on patentability, validity, enforceability and patent term. The following basic tips should avoid some of these pitfalls.
Charles Darwin once said, "It is not necessarily the strongest that survive or the most intelligent, but the one most responsive to change." The same can be said of the life sciences industry. For nearly a decade, life sciences companies have struggled against low productivity in research and development (R&D), loss of patent protection, competition from generics, skyrocketing costs, an ongoing talent shortage and diminishing corporate reputations.
In 2007, legislative initiatives to create a generic biologics pathway stalled before they got started. In fact, innovators and generics from the pharmaceutical and biotechnology industries could not even agree on an appropriate name for these controversial products, often referred to as "follow-on biologics," "biosimilars," "biogenerics" or "comparable biologic products." In 2007 and 2008, several divergent bills were proposed, but the efforts gave way to the presidential and congressional elections. 2009 has seen a resurrection of this debate.
In 1960, when President Kennedy said he wanted U.S. astronauts on the moon by the end of the decade, it seemed impossible. But the government used this single-minded agenda as a policy guide, and in 1969 there was that famous giant leap for mankind.
The versatile chumby just might provide consumers with a little too much information. What other gadget can jolt you out of bed in the morning and then flash images of what you did the night before?
Count Peter Shaw among the chorus of investment industry executives who say they've never seen a financial climate worse than the one we're in now. But don't count him among those without hope.
Even as news of the region's biotech industry remains bleak, San Diego-based Novalar Pharmaceuticals just launched its first new product and has another in development.
In the fight against cancer, more and more doctors are turning to Carlsbad-based Genoptix Medical Laboratories.
Maintaining a 70 percent growth rate via organic growth as well as acquisitions during a recession is no mean feat. It's no wonder that Active Network CEO Dave Alberga is bullish about the future, his company and 2009 revenues.
Learn about key people, innovations and trends in San Diego’s thriving tech and biotech industries.
Find out Who's Who in Tech & Biotech as we profile a few executives turning local companies into regional success stories.
Take a closer look at some of the leading CEOs turning local tech and biotech companies into regional success stories.
Find out how high-tech and biotech companies continue to impact our economy in this annual report. We profile some of the local CEOs and feature a roundtable discussion hosted by Connect.